The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Managing MZL in the frontline setting: exploring chemotherapy-free options for patients
Ariela Noy, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the management of marginal zone lymphoma (MZL), emphasizing the importance of tailoring treatment to the patient’s specific situation. Dr Noy further highlights chemotherapy-free options being investigated. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I was very privileged to actually be an invited author on a paper that’s coming out in Blood, looking at how we address marginal zone lymphoma in the frontline. And what I can tell you is that we still think about it as splenic, nodal, and extranodal. It really needs to be tailored to that situation. And there’s emerging data that probably many patients can be treated with rituximab alone in the right setting...
So I was very privileged to actually be an invited author on a paper that’s coming out in Blood, looking at how we address marginal zone lymphoma in the frontline. And what I can tell you is that we still think about it as splenic, nodal, and extranodal. It really needs to be tailored to that situation. And there’s emerging data that probably many patients can be treated with rituximab alone in the right setting. Some people will receive chemoimmunotherapy. What we’d like to do in the future is allow or facilitate those patients to have chemotherapy-free options if they would be appropriate for immunochemotherapy. And we are opening a study with Miami and they are the lead, looking at a bispecific antibody for marginal zone lymphoma frontline.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
